Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;5(3):193-6.
doi: 10.4103/0976-500X.136101.

Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis

Raffaele Serra  1 , Raffaele Grande  1 , Gianluca Buffone  1 , Edoardo Scarcello  2 , Fabio Tripodi  3 , Pierandrea Rende  4 , Luca Gallelli  4 , Stefano de Franciscis  1
Affiliations

Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis

Raffaele Serra et al. J Pharmacol Pharmacother. 2014 Jul.

Abstract

Objective: To explore the effect of sequential treatment with glucocorticoid and tumor necrosis factor-alpha inhibitors in patients with Takayasu arteritis (TA).

Materials and methods: In five patients with TA, the effects of the sequential treatment with prednisone for 5-7 months and then with adalimumab (ADA) + methotrexate (MTX) or infliximab + MTX, or with ADA only, for 12 months on both clinical and laboratory findings were evaluated.

Results: All treatments improved both symptoms and laboratory parameters without the development of side-effects.

Conclusions: It was hypothesized that MMP-9 and neutrophil gelatinase-associated lipocalin could be markers of the response to the treatments.

Keywords: Adalimumab; infliximab; matrix metalloproteinases-9; methotrexate; neutrophil gelatinase-associated lipocalin; takayasu arteritis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Ishihara T, Haraguchi G, Tezuka D, Kamiishi T, Inagaki H, Isobe M. Diagnosis and assessment of Takayasu arteritis by multiple biomarkers. Circ J. 2013;77:477–83. - PubMed
    1. Kallappa Parameshwarappa S, Mandjiny N, Kavumkal Rajagopalan B, Radhakrishnan N, Samavedam S, Unnikrishnan M. Intact giant abdominal aortic aneurysm due to Takayasu arteritis. Ann Vasc Surg. 2013;27:671.e11–4. - PubMed
    1. Seko Y. Takayasu arteritis: Insights into immunopathology. Jpn Heart J. 2000;41:15–26. - PubMed
    1. Seko Y, Sugishita K, Sato O, Takagi A, Tada Y, Matsuo H, et al. Expression of costimulatory molecules (4-1BBL and Fas) and major histocompatibility class I chain-related A in aortic tissue with Takayasu's arteritis. J Vasc Res. 2004;41:84–90. - PubMed
    1. Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z. Pathogenesis of Takayasu's arteritis: A 2011 update. Autoimmun Rev. 2011;11:61–7. - PubMed

LinkOut - more resources